Choice's forecast indicates significant earnings growth for Park Medi World, expecting revenue to rise from ₹16.8 billion in FY26 to ₹39.4 billion by FY29, with stable EBITDA margins of 26.5%. The brokerage maintains a 'BUY' rating and sets a target price of ₹350.